8 active not recruiting. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Active not recruiting 8 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome obudanersen, Placebo - Angelman Syndrome | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 156 | 2025-06-10 | 2026-11-19 |
| A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS tVNS, intermittent stimulation, tVNS, continuous stimulation - Prader-Willi Syndrome | Phase 3 | Active not recruiting | Foundation for Prader-Willi Research | 102 | 2024-01-08 | 2026-04-06 |
| Oral N-acetylcysteine for Retinitis Pigmentosa N-acetylcysteine, Placebo - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Johns Hopkins University | 485 | 2023-10-11 | 2026-06-15 |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Odevixibat - Alagille Syndrome | Phase 3 | Active not recruiting | Albireo, an Ipsen Company | 62 | 2021-09-03 | 2026-10-23 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-12 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
Down Syndrome (2) · Alagille Syndrome (1) · Angelman Syndrome (1) · Burkitt Lymphoma (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Netherton Syndrome (1) · Polycystic Kidney, Autosomal Dominant (1) · Polycystic liver disease (1) · Prader-Willi Syndrome (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Retinitis Pigmentosa (1) · Usher Syndromes (1)
Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Nervous System Diseases (5) · Chromosome Disorders (4) · Neurologic Manifestations (4) · Intellectual Disability (3) · Neurobehavioral Manifestations (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Imprinting Disorders (2) · Leukemia (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Asparaginase (2) · Cytarabine (2) · Thioguanine (2) · asparaginase erwinia chrysanthemi recombinant (2) · Acetylcysteine (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Daunorubicin (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Leucovorin (1) · Leyk (1) · Mercaptopurine (1) · Methotrexate (1)
Albireo, an Ipsen Company (1) · Camurus AB (1) · Children's Oncology Group (1) · Foundation for Prader-Willi Research (1) · Ionis Pharmaceuticals, Inc. (1) · Johns Hopkins University (1) · National Cancer Institute (NCI) (1) · Quoin Pharmaceuticals (1)
United States (8) · Canada (4) · Germany (4) · Australia (3) · Netherlands (3) · United Kingdom (3) · Belgium (2) · Italy (2) · New Zealand (2) · Poland (2) · Puerto Rico (2) · Austria (1) · France (1) · Israel (1) · Japan (1)
Deepan Singh, MD (1) · Jason N Berman (1) · Joost Drenth, MD (1) · Peter A Campochiaro, MD (1) · Sumit Gupta (1) · Theresa Strong, PhD (1) · Tony Andrasfay (1) · Xiangrong Kong (1)
PMID 33844429, PMID 39356039, PMID 39651791, PMID 41124669, PMID 41282901, PMID 42635483
U10CA180886 (2), 1UG1EY033293 (1), 2023 (1)